Loading…

Complete response to alectinib following crizotinib in an ALK-positive inflammatory myofibroblastic tumor with CNS involvement

Inflammatory myofibroblastic tumor (IMT) is a rare entity that affects mostly children and young adults. The lungs are the most frequent primary site. When feasible, surgical resection is the standard of care and it is associated with long-term survival benefit. Metastatic disease is rare, and centr...

Full description

Saved in:
Bibliographic Details
Published in:Current problems in cancer. Case reports 2021-12, Vol.4, p.100117, Article 100117
Main Authors: Xavier, Camila B., Canedo, Felipe S.N.A., Lima, Fabíola A.S., Melo, Raíssa R., Lima, Luiz Guilherme C.A., Marin, José Flávio G., Souza, Ciro E., Feher, Olavo
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3297-ae520bd1312cd84251cfc52b0a0e62f19a2e5fca47f297a62a5b2952619cbd33
cites cdi_FETCH-LOGICAL-c3297-ae520bd1312cd84251cfc52b0a0e62f19a2e5fca47f297a62a5b2952619cbd33
container_end_page
container_issue
container_start_page 100117
container_title Current problems in cancer. Case reports
container_volume 4
creator Xavier, Camila B.
Canedo, Felipe S.N.A.
Lima, Fabíola A.S.
Melo, Raíssa R.
Lima, Luiz Guilherme C.A.
Marin, José Flávio G.
Souza, Ciro E.
Feher, Olavo
description Inflammatory myofibroblastic tumor (IMT) is a rare entity that affects mostly children and young adults. The lungs are the most frequent primary site. When feasible, surgical resection is the standard of care and it is associated with long-term survival benefit. Metastatic disease is rare, and central nervous system involvement is very infrequent. There is paucity of data regarding systemic treatment of recurrent or metastatic disease but most IMTs present with ALK rearrangements, becoming potential targets to ALK inhibition. Diagnosis of ALK rearrangements by FISH or RT-PCR is standard and discordant results from immunohistochemistry are rare. Crizotinib is considered the standard therapy in ALK-positive cases. Data supporting the use of other ALK inhibitors are scant and derived only from case reports. We report a case of a patient harboring an ALK-positive by IHC, FISH-negative IMT, that initially responded well to crizotinib but progressed in the CNS, presenting a complete CNS response with second-generation ALK inhibitor alectinib.
doi_str_mv 10.1016/j.cpccr.2021.100117
format article
fullrecord <record><control><sourceid>elsevier_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_bb59d42a73c0450c93b1f7c0d0779bb6</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S266662192100065X</els_id><doaj_id>oai_doaj_org_article_bb59d42a73c0450c93b1f7c0d0779bb6</doaj_id><sourcerecordid>S266662192100065X</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3297-ae520bd1312cd84251cfc52b0a0e62f19a2e5fca47f297a62a5b2952619cbd33</originalsourceid><addsrcrecordid>eNp9UU1v1TAQjBBIVG1_ARf_gTxsJ3HwgUP1xEfFUznQu7XerIufnDiyzaseB347boMQJ067Gs2MZnea5o3gO8GFenvc4YqYdpJLUREuxPiiuZBKqVZJoV_-s79urnM-cs7lIIQe-4vm1z7Oa6BCLFFe45KJlcggEBa_eMtcDCE--uWBYfI_4wb6hcHCbg5f2jVmX_yJKuQCzDOUmM5sPkfnbYo2QC4eWfkxx8QeffnO9nffKvcUw4lmWspV88pByHT9Z1429x8_3O8_t4evn273N4cWO6nHFmiQ3E6iExKnd31Njw4HaTlwUtIJDZIGh9CPrtJBSRis1INUQqOduu6yud1spwhHsyY_QzqbCN48AzE9GEg1aSBj7aCnXsLYIe8Hjrqzwo3IJz6O2lpVvbrNC1PMOZH76ye4eSrEHM1zIeapELMVUlXvNxXVK0-eksnoaUGafKq_rjn8f_W_AU52l2o</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Complete response to alectinib following crizotinib in an ALK-positive inflammatory myofibroblastic tumor with CNS involvement</title><source>ScienceDirect Journals</source><creator>Xavier, Camila B. ; Canedo, Felipe S.N.A. ; Lima, Fabíola A.S. ; Melo, Raíssa R. ; Lima, Luiz Guilherme C.A. ; Marin, José Flávio G. ; Souza, Ciro E. ; Feher, Olavo</creator><creatorcontrib>Xavier, Camila B. ; Canedo, Felipe S.N.A. ; Lima, Fabíola A.S. ; Melo, Raíssa R. ; Lima, Luiz Guilherme C.A. ; Marin, José Flávio G. ; Souza, Ciro E. ; Feher, Olavo</creatorcontrib><description>Inflammatory myofibroblastic tumor (IMT) is a rare entity that affects mostly children and young adults. The lungs are the most frequent primary site. When feasible, surgical resection is the standard of care and it is associated with long-term survival benefit. Metastatic disease is rare, and central nervous system involvement is very infrequent. There is paucity of data regarding systemic treatment of recurrent or metastatic disease but most IMTs present with ALK rearrangements, becoming potential targets to ALK inhibition. Diagnosis of ALK rearrangements by FISH or RT-PCR is standard and discordant results from immunohistochemistry are rare. Crizotinib is considered the standard therapy in ALK-positive cases. Data supporting the use of other ALK inhibitors are scant and derived only from case reports. We report a case of a patient harboring an ALK-positive by IHC, FISH-negative IMT, that initially responded well to crizotinib but progressed in the CNS, presenting a complete CNS response with second-generation ALK inhibitor alectinib.</description><identifier>ISSN: 2666-6219</identifier><identifier>EISSN: 2666-6219</identifier><identifier>DOI: 10.1016/j.cpccr.2021.100117</identifier><language>eng</language><publisher>Elsevier Inc</publisher><subject>ALK-rearrangement ; Inflammatory myofibroblastic tumor ; Lung cancer ; Targeted therapy</subject><ispartof>Current problems in cancer. Case reports, 2021-12, Vol.4, p.100117, Article 100117</ispartof><rights>2021 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3297-ae520bd1312cd84251cfc52b0a0e62f19a2e5fca47f297a62a5b2952619cbd33</citedby><cites>FETCH-LOGICAL-c3297-ae520bd1312cd84251cfc52b0a0e62f19a2e5fca47f297a62a5b2952619cbd33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S266662192100065X$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids></links><search><creatorcontrib>Xavier, Camila B.</creatorcontrib><creatorcontrib>Canedo, Felipe S.N.A.</creatorcontrib><creatorcontrib>Lima, Fabíola A.S.</creatorcontrib><creatorcontrib>Melo, Raíssa R.</creatorcontrib><creatorcontrib>Lima, Luiz Guilherme C.A.</creatorcontrib><creatorcontrib>Marin, José Flávio G.</creatorcontrib><creatorcontrib>Souza, Ciro E.</creatorcontrib><creatorcontrib>Feher, Olavo</creatorcontrib><title>Complete response to alectinib following crizotinib in an ALK-positive inflammatory myofibroblastic tumor with CNS involvement</title><title>Current problems in cancer. Case reports</title><description>Inflammatory myofibroblastic tumor (IMT) is a rare entity that affects mostly children and young adults. The lungs are the most frequent primary site. When feasible, surgical resection is the standard of care and it is associated with long-term survival benefit. Metastatic disease is rare, and central nervous system involvement is very infrequent. There is paucity of data regarding systemic treatment of recurrent or metastatic disease but most IMTs present with ALK rearrangements, becoming potential targets to ALK inhibition. Diagnosis of ALK rearrangements by FISH or RT-PCR is standard and discordant results from immunohistochemistry are rare. Crizotinib is considered the standard therapy in ALK-positive cases. Data supporting the use of other ALK inhibitors are scant and derived only from case reports. We report a case of a patient harboring an ALK-positive by IHC, FISH-negative IMT, that initially responded well to crizotinib but progressed in the CNS, presenting a complete CNS response with second-generation ALK inhibitor alectinib.</description><subject>ALK-rearrangement</subject><subject>Inflammatory myofibroblastic tumor</subject><subject>Lung cancer</subject><subject>Targeted therapy</subject><issn>2666-6219</issn><issn>2666-6219</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9UU1v1TAQjBBIVG1_ARf_gTxsJ3HwgUP1xEfFUznQu7XerIufnDiyzaseB347boMQJ067Gs2MZnea5o3gO8GFenvc4YqYdpJLUREuxPiiuZBKqVZJoV_-s79urnM-cs7lIIQe-4vm1z7Oa6BCLFFe45KJlcggEBa_eMtcDCE--uWBYfI_4wb6hcHCbg5f2jVmX_yJKuQCzDOUmM5sPkfnbYo2QC4eWfkxx8QeffnO9nffKvcUw4lmWspV88pByHT9Z1429x8_3O8_t4evn273N4cWO6nHFmiQ3E6iExKnd31Njw4HaTlwUtIJDZIGh9CPrtJBSRis1INUQqOduu6yud1spwhHsyY_QzqbCN48AzE9GEg1aSBj7aCnXsLYIe8Hjrqzwo3IJz6O2lpVvbrNC1PMOZH76ye4eSrEHM1zIeapELMVUlXvNxXVK0-eksnoaUGafKq_rjn8f_W_AU52l2o</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Xavier, Camila B.</creator><creator>Canedo, Felipe S.N.A.</creator><creator>Lima, Fabíola A.S.</creator><creator>Melo, Raíssa R.</creator><creator>Lima, Luiz Guilherme C.A.</creator><creator>Marin, José Flávio G.</creator><creator>Souza, Ciro E.</creator><creator>Feher, Olavo</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope></search><sort><creationdate>202112</creationdate><title>Complete response to alectinib following crizotinib in an ALK-positive inflammatory myofibroblastic tumor with CNS involvement</title><author>Xavier, Camila B. ; Canedo, Felipe S.N.A. ; Lima, Fabíola A.S. ; Melo, Raíssa R. ; Lima, Luiz Guilherme C.A. ; Marin, José Flávio G. ; Souza, Ciro E. ; Feher, Olavo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3297-ae520bd1312cd84251cfc52b0a0e62f19a2e5fca47f297a62a5b2952619cbd33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>ALK-rearrangement</topic><topic>Inflammatory myofibroblastic tumor</topic><topic>Lung cancer</topic><topic>Targeted therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xavier, Camila B.</creatorcontrib><creatorcontrib>Canedo, Felipe S.N.A.</creatorcontrib><creatorcontrib>Lima, Fabíola A.S.</creatorcontrib><creatorcontrib>Melo, Raíssa R.</creatorcontrib><creatorcontrib>Lima, Luiz Guilherme C.A.</creatorcontrib><creatorcontrib>Marin, José Flávio G.</creatorcontrib><creatorcontrib>Souza, Ciro E.</creatorcontrib><creatorcontrib>Feher, Olavo</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>Directory of Open Access Journals</collection><jtitle>Current problems in cancer. Case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xavier, Camila B.</au><au>Canedo, Felipe S.N.A.</au><au>Lima, Fabíola A.S.</au><au>Melo, Raíssa R.</au><au>Lima, Luiz Guilherme C.A.</au><au>Marin, José Flávio G.</au><au>Souza, Ciro E.</au><au>Feher, Olavo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Complete response to alectinib following crizotinib in an ALK-positive inflammatory myofibroblastic tumor with CNS involvement</atitle><jtitle>Current problems in cancer. Case reports</jtitle><date>2021-12</date><risdate>2021</risdate><volume>4</volume><spage>100117</spage><pages>100117-</pages><artnum>100117</artnum><issn>2666-6219</issn><eissn>2666-6219</eissn><abstract>Inflammatory myofibroblastic tumor (IMT) is a rare entity that affects mostly children and young adults. The lungs are the most frequent primary site. When feasible, surgical resection is the standard of care and it is associated with long-term survival benefit. Metastatic disease is rare, and central nervous system involvement is very infrequent. There is paucity of data regarding systemic treatment of recurrent or metastatic disease but most IMTs present with ALK rearrangements, becoming potential targets to ALK inhibition. Diagnosis of ALK rearrangements by FISH or RT-PCR is standard and discordant results from immunohistochemistry are rare. Crizotinib is considered the standard therapy in ALK-positive cases. Data supporting the use of other ALK inhibitors are scant and derived only from case reports. We report a case of a patient harboring an ALK-positive by IHC, FISH-negative IMT, that initially responded well to crizotinib but progressed in the CNS, presenting a complete CNS response with second-generation ALK inhibitor alectinib.</abstract><pub>Elsevier Inc</pub><doi>10.1016/j.cpccr.2021.100117</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2666-6219
ispartof Current problems in cancer. Case reports, 2021-12, Vol.4, p.100117, Article 100117
issn 2666-6219
2666-6219
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_bb59d42a73c0450c93b1f7c0d0779bb6
source ScienceDirect Journals
subjects ALK-rearrangement
Inflammatory myofibroblastic tumor
Lung cancer
Targeted therapy
title Complete response to alectinib following crizotinib in an ALK-positive inflammatory myofibroblastic tumor with CNS involvement
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A25%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Complete%20response%20to%20alectinib%20following%20crizotinib%20in%20an%20ALK-positive%20inflammatory%20myofibroblastic%20tumor%20with%20CNS%20involvement&rft.jtitle=Current%20problems%20in%20cancer.%20Case%20reports&rft.au=Xavier,%20Camila%20B.&rft.date=2021-12&rft.volume=4&rft.spage=100117&rft.pages=100117-&rft.artnum=100117&rft.issn=2666-6219&rft.eissn=2666-6219&rft_id=info:doi/10.1016/j.cpccr.2021.100117&rft_dat=%3Celsevier_doaj_%3ES266662192100065X%3C/elsevier_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3297-ae520bd1312cd84251cfc52b0a0e62f19a2e5fca47f297a62a5b2952619cbd33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true